<?xml version='1.0' encoding='utf-8'?>
<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd">
  <key id="d0" for="node" attr.name="label" attr.type="string" />
  <key id="d1" for="node" attr.name="type" attr.type="string" />
  <key id="d2" for="node" attr.name="community" attr.type="string" />
  <key id="d3" for="edge" attr.name="weight" attr.type="double" />
  <key id="d4" for="edge" attr.name="label" attr.type="string" />
  <key id="d5" for="node" attr.name="description" attr.type="string" />
  <key id="d6" for="edge" attr.name="full_description" attr.type="string" />
  <graph id="G" edgedefault="directed">
    <node id="0">
      <data key="d0">VISTAGEN THERAPEUTICS, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">VISTAGEN THERAPEUTICS, INC. is a biopharmaceutical company that is developing a drug called fasedienol for the treatment of social anxiety disorder. The company is currently facing a lawsuit from investors who allege that it has provided false and misleading information about the drug.

Vistagen Therapeutics, Inc. is a biopharmaceutical company that is focused on developing new treatments for various mental health and central nervous system (CNS) disorders. The company's lead product candidate is fasedienol, which is being developed for the treatment of social anxiety disorder.

According to the company's descriptions, fasedienol is a promising new drug that has the potential to provide relief for individuals suffering from social anxiety disorder. The drug is currently in the clinical development stage, and Vistagen Therapeutics is working to advance it through the regulatory approval process.

However, the company is also facing a lawsuit from investors who allege that it has provided false and misleading information about the drug. The investors claim that the company has made exaggerated claims about the efficacy and safety of fasedienol, and that it has failed to disclose important information about the drug's development and potential risks.

Despite these allegations, Vistagen Therapeutics remains committed to the development of fasedienol and other potential treatments for mental health and CNS disorders. The company has a team of experienced researchers and clinicians who are dedicated to advancing its pipeline of drug candidates.

Overall, Vistagen Therapeutics, Inc. is a biopharmaceutical company that is focused on developing new treatments for mental health and CNS disorders. While the company is facing a lawsuit from investors, it remains committed to the development of its lead product candidate, fasedienol, for the treatment of social anxiety disorder.</data>
    </node>
    <node id="1">
      <data key="d0">PALISADE-2</data>
      <data key="d1">EVENT</data>
      <data key="d2">12.0</data>
      <data key="d5">PALISADE-2 is a clinical trial conducted by Vistagen Therapeutics for their drug candidate fasedienol. The trial has reported positive results, building on the success of previous clinical trials for the same drug.

Fasedienol is Vistagen's investigational drug that is being developed for the treatment of various medical conditions. The PALISADE-2 trial is the latest in a series of clinical studies evaluating the safety and efficacy of fasedienol.

The provided descriptions indicate that the PALISADE-2 trial, as well as previous clinical trials for fasedienol, have yielded positive results. This suggests that the drug has shown promise in demonstrating its therapeutic potential and meeting key clinical endpoints.

While the exact details of the PALISADE-2 trial and the previous studies are not provided, the consistent positive outcomes across these trials suggest that fasedienol may be a viable treatment option for the conditions it is being developed to address.

Vistagen, the pharmaceutical company behind fasedienol, is likely encouraged by the positive results from the PALISADE-2 trial and the earlier clinical studies. These findings could pave the way for further development, regulatory approval, and potential commercialization of the drug, pending successful completion of additional clinical trials and regulatory review.

It is important to note that the provided information does not indicate any contradictions or inconsistencies between the descriptions of the PALISADE-2 trial and the previous clinical trials for fasedienol. The consistent positive results across these studies suggest a coherent and promising development pathway for the drug.

In summary, the PALISADE-2 clinical trial, along with previous positive trials for Vistagen's drug candidate fasedienol, indicates that the drug has shown promising results in clinical evaluations. These findings could potentially contribute to the further development and potential approval of fasedienol as a new treatment option, pending the successful completion of additional clinical studies and regulatory review.</data>
    </node>
    <node id="2">
      <data key="d0">PALISADE-3</data>
      <data key="d1">EVENT</data>
      <data key="d2">11.0</data>
      <data key="d5">The PALISADE-3 is an ongoing Phase 3 clinical trial being conducted by Vistagen Therapeutics for their drug candidate fasedienol. The trial is a crucial step in the development of fasedienol, as it aims to evaluate the safety and efficacy of the drug in a larger patient population.

Vistagen believes that the PALISADE-3 trial has a strong likelihood of success, based on enhancements and operational changes made to the study design and execution. The company is confident in the potential of fasedienol to address the unmet medical needs of the target patient population.

The PALISADE-3 trial is the current Phase 3 clinical trial for fasedienol that Vistagen is conducting. It is the subject of a lawsuit, which suggests that there may be some legal or regulatory challenges associated with the trial. However, the details of the lawsuit and its potential impact on the trial are not provided in the given information.

Overall, the PALISADE-3 trial represents a significant milestone in the development of Vistagen's fasedienol drug. The company is optimistic about the trial's prospects and believes that the enhancements and operational changes made to the study will contribute to its success. The trial is a crucial step in the journey to bring this potential new treatment option to patients in need.</data>
    </node>
    <node id="3">
      <data key="d0">ROSEN, NATIONAL TRIAL LAWYERS</data>
      <data key="d1" />
      <data key="d2">12.0</data>
      <data key="d5" />
    </node>
    <node id="4">
      <data key="d0">VISTAGEN</data>
      <data key="d1" />
      <data key="d2">11.0</data>
      <data key="d5" />
    </node>
    <node id="5">
      <data key="d0">FASEDIENOL</data>
      <data key="d1" />
      <data key="d2">11.0</data>
      <data key="d5" />
    </node>
    <node id="6">
      <data key="d0">SOCIAL ANXIETY DISORDER</data>
      <data key="d1">GEO</data>
      <data key="d2">11.0</data>
      <data key="d5">The medical condition that Vistagen's drug fasedienol is being developed to treat</data>
    </node>
    <node id="7">
      <data key="d0">DEFENDANTS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">11.0</data>
      <data key="d5">The defendants named in the lawsuit against Vistagen</data>
    </node>
    <node id="8">
      <data key="d0">INVESTORS</data>
      <data key="d1">PERSON</data>
      <data key="d2">11.0</data>
      <data key="d5">The investors who suffered damages when the true details about the PALISADE-3 trial entered the market</data>
    </node>
    <node id="9">
      <data key="d0">GAUZY LTD.</data>
      <data key="d1" />
      <data key="d2">14.0</data>
      <data key="d5" />
    </node>
    <node id="10">
      <data key="d0">ROSEN, GLOBAL INVESTOR COUNSEL</data>
      <data key="d1" />
      <data key="d2">12.0</data>
      <data key="d5" />
    </node>
    <node id="11">
      <data key="d0">ROSEN LAW FIRM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">14.0</data>
      <data key="d5">The Rosen Law Firm is a global investor rights law firm that specializes in representing investors in class action lawsuits. The firm has filed several high-profile cases on behalf of investors in various companies.

One of the cases the Rosen Law Firm has been involved in is a class action lawsuit against Instacart, the grocery delivery service. The firm has filed this lawsuit on behalf of Instacart investors, alleging that the company made false and misleading statements about its business and financial performance.

The Rosen Law Firm has also filed a class action lawsuit on behalf of investors in Vistagen Therapeutics, a biopharmaceutical company. The lawsuit alleges that the company made false and misleading statements about the development and potential approval of its drug candidates.

In addition to these cases, the Rosen Law Firm is representing investors in a class action lawsuit against Gauzy Ltd., a technology company. The lawsuit alleges that the company made false and misleading statements about its business and financial performance.

The firm is also representing investors in a securities class action lawsuit against Bitdeer Technologies Group, a cryptocurrency mining company. The lawsuit alleges that the company made false and misleading statements about its business and financial performance.

Finally, the Rosen Law Firm is representing investors in a securities class action lawsuit against Alexandria Real Estate Equities, Inc., a real estate investment trust. The lawsuit alleges that the company made false and misleading statements about its business and financial performance.

Laurence Rosen, an expert attorney at the Rosen Law Firm, has extensive experience in representing investors in class action lawsuits. The firm is known for its commitment to protecting the rights of investors and holding companies accountable for their actions.

Overall, the Rosen Law Firm has been involved in several high-profile cases on behalf of investors, demonstrating its expertise and dedication to protecting the rights of its clients.</data>
    </node>
    <node id="12">
      <data key="d0">PHILLIP KIM</data>
      <data key="d1">PERSON</data>
      <data key="d2">14.0</data>
      <data key="d5">Phillip Kim is an attorney at the Rosen Law Firm who is handling several class action lawsuits. Based on the information provided, he is involved in the following cases:

1. Vistagen Therapeutics class action lawsuit: Phillip Kim is handling the class action lawsuit against Vistagen Therapeutics.

2. Bitdeer Technologies Group securities class action lawsuit: Phillip Kim is handling the class action lawsuit against Bitdeer Technologies Group.

3. Instacart class action lawsuit: Phillip Kim is handling the class action lawsuit against Instacart.

4. Gauzy Ltd. class action lawsuit: Phillip Kim is handling the class action lawsuit against Gauzy Ltd.

5. Oracle securities class action lawsuit: Phillip Kim is handling the class action lawsuit against Oracle.

6. Alexandria Real Estate Equities, Inc. class action lawsuit: Phillip Kim is handling the class action lawsuit against Alexandria Real Estate Equities, Inc.

The descriptions provided do not contain any contradictory information about Phillip Kim's role or the cases he is involved in. He is consistently described as an attorney at the Rosen Law Firm who is handling various class action lawsuits against different companies and entities.

In summary, Phillip Kim is an experienced attorney at the Rosen Law Firm who is currently handling multiple class action lawsuits, including those against Vistagen Therapeutics, Bitdeer Technologies Group, Instacart, Gauzy Ltd., Oracle, and Alexandria Real Estate Equities, Inc. He is known for his expertise in representing clients in complex class action litigation.</data>
    </node>
    <node id="13">
      <data key="d0">LAURENCE ROSEN</data>
      <data key="d1">PERSON</data>
      <data key="d2">9.0</data>
      <data key="d5">Laurence Rosen is the founding partner of the Rosen Law Firm, a prominent law firm specializing in securities class action litigation. He has been recognized as a Titan of the Plaintiffs' Bar by Law360, a leading legal publication, in 2020.

Rosen is an experienced and successful securities class action attorney, having litigated and obtained multimillion-dollar recoveries in over 150 securities class actions over the past 30 years. He is known for his expertise in this field and has been praised for his ability to achieve significant results for his clients.

As the founding partner of the Rosen Law Firm, Rosen has built a reputation as one of the leading plaintiff financial lawyers in the country. The firm has a strong track record of success in representing investors and consumers in complex legal matters, and Rosen's leadership has been instrumental in the firm's growth and success.

Rosen's recognition as a Titan of the Plaintiffs' Bar is a testament to his dedication and commitment to his clients. This prestigious award is given to a select group of attorneys who have demonstrated exceptional skill and expertise in their respective fields, and Rosen's inclusion in this group is a reflection of his outstanding achievements and contributions to the legal profession.

Overall, Laurence Rosen is a highly respected and accomplished securities class action attorney who has made significant contributions to the field of plaintiff-side litigation. His leadership and expertise have been instrumental in the success of the Rosen Law Firm, and he continues to be a driving force in the legal community.</data>
    </node>
    <node id="14">
      <data key="d0">BITDEER TECHNOLOGIES GROUP</data>
      <data key="d1" />
      <data key="d2">13.0</data>
      <data key="d5" />
    </node>
    <node id="15">
      <data key="d0">SEALMINER</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">13.0</data>
      <data key="d5">SEALMINER is a Bitcoin mining machine produced by Bitdeer Technologies Group</data>
    </node>
    <node id="16">
      <data key="d0">SEAL04 ASIC</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">13.0</data>
      <data key="d5">SEAL04 ASIC is a chip technology used in Bitdeer's SEALMINER A4 rigs</data>
    </node>
    <node id="17">
      <data key="d0">VISTAGEN THERAPEUTICS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">Vistagen Therapeutics is a company that Laurence Rosen, as a national trial lawyer, has encouraged investors in to secure counsel before important deadlines.</data>
    </node>
    <node id="18">
      <data key="d0">ORACLE CORPORATION</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">Oracle Corporation is a technology company that has faced various legal and financial challenges in recent years. 

According to the information provided, Oracle Corporation is currently involved in a securities class action lawsuit. Laurence Rosen, a leading trial attorney, has encouraged investors in Oracle Corporation to secure counsel before important deadlines related to this lawsuit.

Additionally, Oracle Corporation has issued senior notes pursuant to a Shelf Registration Statement filed with the U.S. Securities and Exchange Commission (SEC). This suggests that the company has been actively raising capital through debt financing.

While the descriptions provided do not directly contradict each other, they highlight different aspects of Oracle Corporation's legal and financial situation. The securities class action lawsuit indicates that the company is facing allegations of securities-related misconduct, which could have significant financial and reputational implications. The issuance of senior notes, on the other hand, suggests that Oracle Corporation is actively managing its capital structure and seeking to raise funds for its operations or other corporate purposes.

Overall, Oracle Corporation appears to be navigating a complex legal and financial landscape. The company's involvement in a securities class action lawsuit, as well as its efforts to raise capital through debt financing, suggest that it is facing challenges that require careful management and oversight. Investors and other stakeholders may want to closely monitor the company's developments and seek professional advice before making any investment decisions.</data>
    </node>
    <node id="19">
      <data key="d0">BLUE OWL</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">Blue Owl is a company that Laurence Rosen, as a leading trial attorney, has encouraged investors in to secure counsel before important deadlines.</data>
    </node>
    <node id="20">
      <data key="d0">ALEXANDRIA REAL ESTATE EQUITIES</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">Alexandria Real Estate Equities is a company that Laurence Rosen, as a leading trial attorney, has encouraged investors in to secure counsel before important deadlines.</data>
    </node>
    <node id="21">
      <data key="d0">MERCURY SYSTEMS INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">Mercury Systems Inc. is a company that Laurence Rosen, as a leading trial attorney, has encouraged investors in to secure counsel before important deadlines.</data>
    </node>
    <node id="22">
      <data key="d0">GAUZY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">Gauzy is a company that Laurence Rosen, as a national trial counsel, has encouraged investors in to secure counsel before important deadlines.</data>
    </node>
    <node id="23">
      <data key="d0">MAPLEBEAR INC. (D/B/A INSTACART)</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">Maplebear Inc. (d/b/a Instacart) is a company that Laurence Rosen, as a leading trial attorney, has encouraged investors in to secure counsel before important deadlines.</data>
    </node>
    <node id="24">
      <data key="d0">IMX TOKEN</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">The IMX Token is a cryptocurrency token that was issued by Immutable, a company that is currently under investigation by the U.S. Securities and Exchange Commission (SEC). Laurence Rosen, a national trial lawyer, has encouraged investors in the IMX Token to secure legal counsel before important deadlines related to the token.

Immutable is a company that developed the IMX Token, which is a cryptocurrency token that operates on the Ethereum blockchain. The IMX Token is used within the Immutable ecosystem, which includes various decentralized applications (dApps) and gaming platforms.

The SEC is currently investigating Immutable, the company behind the IMX Token, regarding potential regulatory issues or violations. The nature and scope of the SEC's investigation are not publicly known, but it is likely related to the issuance and distribution of the IMX Token.

Laurence Rosen, a prominent national trial lawyer, has advised investors in the IMX Token to seek legal counsel before important deadlines related to the token. This suggests that there may be legal or regulatory concerns surrounding the IMX Token, and investors may need to take action to protect their interests.

It is important to note that the information provided is limited, and there may be additional details or context that are not included in the given descriptions. The summary provided here is based on the information available and aims to present a coherent and comprehensive overview of the IMX Token and the related circumstances.

In conclusion, the IMX Token is a cryptocurrency token issued by Immutable, a company that is currently under investigation by the SEC. Investors in the IMX Token have been advised by a national trial lawyer to secure legal counsel before important deadlines, indicating potential legal or regulatory issues surrounding the token.</data>
    </node>
    <node id="25">
      <data key="d0">BITDEER</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">Bitdeer is a company that Laurence Rosen, as a trusted trial lawyer, has encouraged investors in to secure counsel before important deadlines.</data>
    </node>
    <node id="26">
      <data key="d0">REFLECTOR.COM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">13.0</data>
      <data key="d5">Reflector.com is the website where the article about the Bitdeer Technologies Group legal deadline is published)("relationship"
Reflector.com is the website where the article about the Bitdeer Technologies Group legal deadline is published</data>
    </node>
    <node id="27">
      <data key="d0">NASDAQ</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">5.0</data>
      <data key="d5">NASDAQ is a major stock exchange located in the United States. It is the second-largest stock exchange in the world by market capitalization, behind only the New York Stock Exchange (NYSE).

NASDAQ is the stock exchange where Instacart, a leading online grocery delivery service, is publicly traded. Instacart's shares are listed and traded on the NASDAQ exchange, allowing investors to buy and sell the company's stock.

In addition to Instacart, NASDAQ is also the stock exchange on which Vistagen Therapeutics, a clinical-stage biopharmaceutical company, is listed. Vistagen Therapeutics' shares are traded on the NASDAQ exchange, providing investors with the opportunity to participate in the company's growth and development.

NASDAQ is known for its focus on technology, biotechnology, and other high-growth industries. Many of the world's most innovative and influential companies, such as Apple, Microsoft, Amazon, and Google, are listed on the NASDAQ exchange. This makes NASDAQ a hub for investors seeking exposure to the latest advancements in technology, healthcare, and other cutting-edge sectors.

The NASDAQ exchange operates as an electronic market, where trades are executed through a network of computers and electronic communication systems, rather than a physical trading floor. This electronic trading model allows for faster and more efficient transactions, as well as increased transparency and accessibility for investors.

Overall, NASDAQ is a prominent and influential stock exchange that plays a significant role in the global financial markets. By hosting the shares of companies like Instacart and Vistagen Therapeutics, NASDAQ provides a platform for these businesses to raise capital, increase their visibility, and offer investment opportunities to a wide range of investors.</data>
    </node>
    <node id="28">
      <data key="d0">SHELF REGISTRATION STATEMENT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">The Shelf Registration Statement was filed by Oracle Corporation with the SEC on March 15, 2024 and supplemented on September 25, 2025</data>
    </node>
    <node id="29">
      <data key="d0">SEC</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">The U.S. Securities and Exchange Commission (SEC) is the regulatory body that Oracle Corporation filed the Shelf Registration Statement with</data>
    </node>
    <node id="30">
      <data key="d0">INSTACART</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">5.0</data>
      <data key="d5">Instacart is an online grocery shopping and delivery service owned by Maplebear Inc.</data>
    </node>
    <node id="31">
      <data key="d0">MAPLEBEAR INC.</data>
      <data key="d1" />
      <data key="d2">5.0</data>
      <data key="d5" />
    </node>
    <node id="32">
      <data key="d0">SEPTEMBER 19, 2023</data>
      <data key="d1">EVENT</data>
      <data key="d2">5.0</data>
      <data key="d5">Instacart's initial public offering (IPO) occurred on this date</data>
    </node>
    <node id="33">
      <data key="d0">OCTOBER 1, 2023</data>
      <data key="d1">EVENT</data>
      <data key="d2">5.0</data>
      <data key="d5">The class period for the Instacart securities class action lawsuit ended on this date</data>
    </node>
    <node id="34">
      <data key="d0">MARCH 25, 2024</data>
      <data key="d1">EVENT</data>
      <data key="d2">5.0</data>
      <data key="d5">The deadline for investors to join the Instacart class action lawsuit as lead plaintiff</data>
    </node>
    <node id="35">
      <data key="d0">NEW YORK UNIVERSITY SCHOOL OF LAW</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">New York University School of Law is the law school where Laurence Rosen graduated from with a J.D. degree.</data>
    </node>
    <node id="36">
      <data key="d0">UNIVERSITY OF CHICAGO GRADUATE SCHOOL OF BUSINESS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">The University of Chicago Graduate School of Business is where Laurence Rosen earned his M.B.A. in Finance and Accounting.</data>
    </node>
    <node id="37">
      <data key="d0">EMORY UNIVERSITY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">Emory University is where Laurence Rosen earned his B.A. in Economics.</data>
    </node>
    <node id="38">
      <data key="d0">DISTRICT OF NEW JERSEY</data>
      <data key="d1">GEO</data>
      <data key="d2">9.0</data>
      <data key="d5">Laurence Rosen served as a law clerk to the Honorable Stanley S. Brotman, Senior United States District Judge for the District of New Jersey.</data>
    </node>
    <node id="39">
      <data key="d0">SKADDEN ARPS SLATE MEAGHER &amp; FLOM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">Skadden Arps Slate Meagher &amp; Flom is a prominent law firm where Laurence Rosen, the subject of this summary, worked as an associate. The firm is based in New York City and is known for its expertise in various legal practice areas, including securities class action and derivative litigation matters.

According to the provided descriptions, Laurence Rosen entered private practice and joined Skadden Arps Slate Meagher &amp; Flom as an associate. During his time at the firm, he participated in securities class action and derivative litigation matters, leveraging the firm's expertise in these areas.

The descriptions do not present any contradictory information about Laurence Rosen's association with Skadden Arps Slate Meagher &amp; Flom. The consistent details provided indicate that he worked as an associate at the firm, where he was involved in securities-related litigation and other legal matters.

In summary, Skadden Arps Slate Meagher &amp; Flom is a reputable law firm in New York City, and Laurence Rosen, the individual of interest, worked as an associate at the firm, participating in securities class action and derivative litigation matters during his time there.</data>
    </node>
    <node id="40">
      <data key="d0">ALIBABA HOLDINGS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">Laurence Rosen was the lead attorney who directed the successful litigation against Alibaba Holdings arising from its $25 billion IPO, achieving a $250 million settlement.</data>
    </node>
    <node id="41">
      <data key="d0">FIAT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">Laurence Rosen was one of the lead attorneys in the $110 million settlement obtained from FIAT following its merger with Chrysler and its listing on the NYSE.
FIAT is a company that Laurence Rosen was one of the lead attorneys in obtaining a $110 million settlement from following its merger with Chrysler and listing on the NYSE.</data>
    </node>
    <node id="42">
      <data key="d0">TEXTAINER PARTNERSHIPS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">Laurence Rosen was one of the lead trial attorneys in the fiduciary duty litigation against the Textainer partnerships arising from its sale of the partnership assets, resulting in a $10 million recovery for limited partners following a bench trial.
Textainer Partnerships is a company that Laurence Rosen was one of the lead trial attorneys in a fiduciary duty litigation against, resulting in a $10 million recovery for limited partners.</data>
    </node>
    <node id="43">
      <data key="d0">THE ROSEN LAW FIRM</data>
      <data key="d1" />
      <data key="d2">10.0</data>
      <data key="d5" />
    </node>
    <node id="44">
      <data key="d0">PHIL KIM</data>
      <data key="d1">PERSON</data>
      <data key="d2">8.0</data>
      <data key="d5">Phil Kim is a lawyer at The Rosen Law Firm, P.A. who has been recognized as one of the leading plaintiff financial lawyers by Lawdragon.</data>
    </node>
    <node id="45">
      <data key="d0">JACOB GOLDBERG</data>
      <data key="d1">PERSON</data>
      <data key="d2">7.0</data>
      <data key="d5">Jacob Goldberg is a lawyer at The Rosen Law Firm, P.A. who has been recognized as one of the leading plaintiff financial lawyers by Lawdragon.</data>
    </node>
    <node id="46">
      <data key="d0">SANDRIDGE MISSISSIPPIAN TRUST I</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">7.0</data>
      <data key="d5">SandRidge Mississippian Trust I is an organization involved in a proposed partial class action settlement announced by The Rosen Law Firm, P.A.</data>
    </node>
    <node id="47">
      <data key="d0">SANDRIDGE MISSISSIPPIAN TRUST II</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">7.0</data>
      <data key="d5">SandRidge Mississippian Trust II is an organization involved in a proposed partial class action settlement announced by The Rosen Law Firm, P.A.</data>
    </node>
    <node id="48">
      <data key="d0">INDIVIOR PLC</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">7.0</data>
      <data key="d5">Indivior PLC is an organization involved in a proposed securities class action settlement announced by The Rosen Law Firm, P.A.</data>
    </node>
    <node id="49">
      <data key="d0">PPDAI GROUP INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">7.0</data>
      <data key="d5">PPDAI Group Inc. is an organization involved in a proposed class action settlement announced by The Rosen Law Firm, P.A.</data>
    </node>
    <node id="50">
      <data key="d0">ACER THERAPEUTICS INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">7.0</data>
      <data key="d5">Acer Therapeutics Inc. is an organization involved in a proposed class action settlement announced by The Rosen Law Firm, P.A.</data>
    </node>
    <node id="51">
      <data key="d0">FIAT CHRYSLER AUTOMOBILES N.V.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">7.0</data>
      <data key="d5">Fiat Chrysler Automobiles N.V. is an organization for which The Rosen Law Firm, P.A. obtained a $110 million settlement for investors.</data>
    </node>
    <node id="52">
      <data key="d0">ALIBABA GROUP HOLDING LIMITED</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">7.0</data>
      <data key="d5">Alibaba Group Holding Limited is an organization for which The Rosen Law Firm, P.A. obtained a $250 million settlement for investors.</data>
    </node>
    <node id="53">
      <data key="d0">CHANTICLEER HOLDINGS, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">7.0</data>
      <data key="d5">Chanticleer Holdings, Inc. is an organization for which The Rosen Law Firm, P.A. was appointed lead counsel in a class action.</data>
    </node>
    <node id="54">
      <data key="d0">THE ROSEN LAW FIRM, P.A.</data>
      <data key="d1" />
      <data key="d2">7.0</data>
      <data key="d5" />
    </node>
    <node id="55">
      <data key="d0">LAWDRAGON 500</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">8.0</data>
      <data key="d5">The Lawdragon 500 is a list of leading plaintiff financial lawyers that has recognized Laurence Rosen, Phil Kim, and Jacob Goldberg.</data>
    </node>
    <node id="56">
      <data key="d0">NEW YORK CITY</data>
      <data key="d1">GEO</data>
      <data key="d2">10.0</data>
      <data key="d5">New York City is the location of The Rosen Law Firm, where Laurence Rosen is based.</data>
    </node>
    <node id="57">
      <data key="d0">THE NATIONAL TRIAL LAWYERS TOP 100</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">The National Trial Lawyers Top 100 is an organization that recognizes the top 100 trial lawyers in the United States.</data>
    </node>
    <node id="58">
      <data key="d0">MCCARTER &amp; ENGLISH</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">McCarter &amp; English is a law firm where Laurence Rosen worked as an associate, specializing in securities and business litigation.</data>
    </node>
    <node id="59">
      <data key="d0">SOLTON ROSEN &amp; BALAKHOVSKY LLP</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">Solton Rosen &amp; Balakhovsky LLP is a law firm where Laurence Rosen practiced general securities and commercial litigation in New York City before founding The Rosen Law Firm.</data>
    </node>
    <node id="60">
      <data key="d0">ALIBABA GROUP HOLDINGS LTD.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">Alibaba Group Holdings Ltd. is a company for which Laurence Rosen, as sole lead counsel, secured a $250 million class action settlement - the largest settlement involving a Chinese issuer.</data>
    </node>
    <node id="61">
      <data key="d0">FIAT CHRYSLER AUTOMOBILES, N.V.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">Fiat Chrysler Automobiles, N.V. is a company for which Laurence Rosen, as co-lead counsel, secured a $110 million class action settlement.</data>
    </node>
    <node id="62">
      <data key="d0">ALEXANDRIA REAL ESTATE EQUITIES, INC.</data>
      <data key="d1" />
      <data key="d2">14.0</data>
      <data key="d5" />
    </node>
    <node id="63">
      <data key="d0">LONG ISLAND CITY</data>
      <data key="d1">GEO</data>
      <data key="d2">14.0</data>
      <data key="d5">Long Island City is a property owned by Alexandria Real Estate Equities, Inc. that is the subject of the securities class action lawsuit.</data>
    </node>
    <node id="64">
      <data key="d0">PALISADE-2 CLINICAL TRIAL</data>
      <data key="d1">EVENT</data>
      <data key="d2">12.0</data>
      <data key="d5">A previous clinical trial for Vistagen's drug fasedienol that had positive results</data>
    </node>
    <node id="65">
      <data key="d0">PALISADE-3 CLINICAL TRIAL</data>
      <data key="d1">EVENT</data>
      <data key="d2">12.0</data>
      <data key="d5">The current Phase 3 clinical trial for Vistagen's drug fasedienol that is the subject of the lawsuit</data>
    </node>
    <node id="66">
      <data key="d0">MARCH 16, 2026</data>
      <data key="d1">EVENT</data>
      <data key="d2">12.0</data>
      <data key="d5">The deadline for investors to move the court to serve as lead plaintiff in the class action lawsuit</data>
    </node>
    <node id="67">
      <data key="d0">VISTAGEN COMMON STOCK</data>
      <data key="d1" />
      <data key="d2">12.0</data>
      <data key="d5" />
    </node>
    <edge id="e0" source="0" target="3">
      <data key="d3">16.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Vistagen Therapeutics stock during the class period</data>
    </edge>
    <edge id="e1" source="0" target="1">
      <data key="d3">35.0</data>
      <data key="d4">biopharmaceutical company that...</data>
      <data key="d6">VISTAGEN THERAPEUTICS, INC. is a biopharmaceutical company that is developing a drug called fasedienol. The company has conducted multiple clinical trials for this drug, including the PALISADE-2 trial.

The descriptions provided present some contradictory information about the PALISADE-2 clinical trial for fasedienol. One description states that the PALISADE-2 trial had positive results for Vistagen's drug fasedienol. Another description, however, suggests that Vistagen allegedly misrepresented the positive results from the previous PALISADE-2 trial.

Despite these contradictions, the overall information indicates that the PALISADE-2 clinical trial for Vistagen's drug fasedienol had positive results. The company has cited these positive results from the PALISADE-2 trial as supporting the likelihood of success for the ongoing PALISADE-3 trial.

In summary, Vistagen Therapeutics, Inc. is a biopharmaceutical company that is developing a drug called fasedienol. The company has conducted multiple clinical trials for this drug, including the PALISADE-2 trial, which had positive results. While there are some contradictions in the descriptions provided, the overall information suggests that Vistagen has cited the positive results from the PALISADE-2 trial as supporting the likelihood of success for the ongoing PALISADE-3 trial.</data>
    </edge>
    <edge id="e2" source="0" target="2">
      <data key="d3">13.0</data>
      <data key="d4">biopharmaceutical company focused...</data>
      <data key="d6">Vistagen Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. One of their key drug candidates is fasedienol, which is currently undergoing a Phase 3 clinical trial called PALISADE-3.

The PALISADE-3 clinical trial is the pivotal Phase 3 trial for Vistagen's drug fasedienol. Fasedienol is being developed as a potential treatment for various CNS disorders. Vistagen has made enhancements and operational changes to the PALISADE-3 clinical trial, which the company believes will lead to a strong likelihood of success in Phase 3.

However, Vistagen's current PALISADE-3 clinical trial for fasedienol has also been the subject of a lawsuit alleging that the company provided false and misleading information. The lawsuit claims that Vistagen made statements about the PALISADE-3 trial that were not accurate or complete.

Despite the lawsuit, Vistagen remains committed to the development of fasedienol and the successful completion of the PALISADE-3 trial. The company has stated that the enhancements and operational changes made to the trial are designed to improve the likelihood of a positive outcome.

In summary, Vistagen Therapeutics, Inc. is a biopharmaceutical company developing the drug fasedienol, which is currently in a Phase 3 clinical trial called PALISADE-3. The company has made improvements to the trial, but it has also been the subject of a lawsuit alleging the provision of false and misleading information. Vistagen remains focused on the successful completion of the PALISADE-3 trial and the potential approval and commercialization of fasedienol as a treatment for CNS disorders.</data>
    </edge>
    <edge id="e3" source="1" target="4">
      <data key="d3">16.0</data>
      <data key="d4">PALISADE-2 clinical trial...</data>
      <data key="d6">Vistagen conducted the PALISADE-2 clinical trial for fasedienol, which had positive results</data>
    </edge>
    <edge id="e4" source="2" target="4">
      <data key="d3">16.0</data>
      <data key="d4">conducting PALISADE-3 Phase...</data>
      <data key="d6">Vistagen is currently conducting the PALISADE-3 Phase 3 clinical trial for fasedienol</data>
    </edge>
    <edge id="e5" source="4" target="5">
      <data key="d3">10.0</data>
      <data key="d4">investigational drug candidate...</data>
      <data key="d6">Fasedienol is Vistagen's investigational drug candidate for the treatment of social anxiety disorder</data>
    </edge>
    <edge id="e6" source="4" target="7">
      <data key="d3">8.0</data>
      <data key="d4">statements about Vistagen's...</data>
      <data key="d6">The defendants made statements about Vistagen's drug fasedienol and its clinical trials</data>
    </edge>
    <edge id="e7" source="4" target="8">
      <data key="d3">1.0</data>
      <data key="d4">due Vistagen's allegedly...</data>
      <data key="d6">Investors suffered damages due to Vistagen's allegedly false and misleading statements about the PALISADE-3 trial</data>
    </edge>
    <edge id="e8" source="5" target="6">
      <data key="d3">9.0</data>
      <data key="d4">developed Vistagen...</data>
      <data key="d6">Fasedienol is being developed by Vistagen as a treatment for social anxiety disorder</data>
    </edge>
    <edge id="e9" source="0" target="10">
      <data key="d3">2.0</data>
      <data key="d4">Counsel encouraging Vistagen...</data>
      <data key="d6">Rosen, Global Investor Counsel is encouraging Vistagen Therapeutics, Inc. investors to take action</data>
    </edge>
    <edge id="e10" source="11" target="14">
      <data key="d3">18.0</data>
      <data key="d4">Firm representing investors...</data>
      <data key="d6">The Rosen Law Firm is representing investors in a securities class action lawsuit against Bitdeer Technologies Group</data>
    </edge>
    <edge id="e11" source="11" target="12">
      <data key="d3">67.0</data>
      <data key="d4">Firm legal practice...</data>
      <data key="d6">The Rosen Law Firm is a legal practice that specializes in handling class action lawsuits. Phillip Kim is an attorney who works at the Rosen Law Firm and is responsible for managing several high-profile cases.

According to the provided information, Phillip Kim is the attorney at the Rosen Law Firm who is handling the class action lawsuit against Bitdeer Technologies Group. He is also the attorney responsible for the class action lawsuit against Gauzy Ltd., as well as the class action lawsuit against Instacart.

Additionally, Phillip Kim is the attorney at the Rosen Law Firm who is handling the class action lawsuit against Vistagen Therapeutics. He is also the attorney responsible for the class action lawsuit against Alexandria Real Estate Equities, Inc.

The Rosen Law Firm and Phillip Kim appear to have extensive experience in handling complex class action lawsuits across a variety of industries, including technology, healthcare, and real estate. The firm and its attorneys are known for their expertise in securities law and their commitment to protecting the rights of investors and consumers.

Overall, the Rosen Law Firm, led by attorney Phillip Kim, is a prominent legal practice that is actively involved in several high-profile class action lawsuits, demonstrating its commitment to holding companies accountable and seeking justice for its clients.</data>
    </edge>
    <edge id="e12" source="11" target="13">
      <data key="d3">58.0</data>
      <data key="d4">Firm national trial...</data>
      <data key="d6">The Rosen Law Firm is a national trial law firm that represents investors. Laurence Rosen is the founding partner of the Rosen Law Firm.

Laurence Rosen is an expert attorney at the Rosen Law Firm. He is currently handling several class action lawsuits on behalf of investors. These include the class action lawsuit against Alexandria Real Estate Equities, Inc., the Bitdeer Technologies Group securities class action lawsuit, and the Gauzy Ltd. class action lawsuit.

The Rosen Law Firm, under Laurence Rosen's leadership, is representing investors in these cases. Rosen has extensive experience in securities class action lawsuits and is known for his expertise in this area of law.

In the case against Alexandria Real Estate Equities, Inc., the Rosen Law Firm is handling the class action lawsuit on behalf of investors. Laurence Rosen, as the founding partner, is overseeing this litigation.

Similarly, the Rosen Law Firm is representing investors in the Bitdeer Technologies Group securities class action lawsuit, with Laurence Rosen leading the legal team.

Additionally, the Rosen Law Firm, under Laurence Rosen's guidance, is representing investors in the Gauzy Ltd. class action lawsuit.

Laurence Rosen and the Rosen Law Firm have a proven track record of successfully representing investors in complex securities litigation. Their expertise and dedication to protecting the rights of investors have earned them a reputation as a leading firm in this field.

In summary, Laurence Rosen is the founding partner of the Rosen Law Firm, a national trial law firm that specializes in representing investors in class action lawsuits. Rosen and his firm are currently handling several high-profile cases, including the class action lawsuits against Alexandria Real Estate Equities, Inc., Bitdeer Technologies Group, and Gauzy Ltd., demonstrating their commitment to safeguarding the interests of investors.</data>
    </edge>
    <edge id="e13" source="14" target="15">
      <data key="d3">8.0</data>
      <data key="d4">produces SEALMINER Bitcoin...</data>
      <data key="d6">Bitdeer Technologies Group produces the SEALMINER Bitcoin mining machines</data>
    </edge>
    <edge id="e14" source="14" target="16">
      <data key="d3">1.0</data>
      <data key="d4">uses SEAL04 ASIC...</data>
      <data key="d6">Bitdeer Technologies Group uses the SEAL04 ASIC chip technology in its SEALMINER A4 rigs</data>
    </edge>
    <edge id="e15" source="17" target="13">
      <data key="d3">2.0</data>
      <data key="d4">national trial lawyer,...</data>
      <data key="d6">Laurence Rosen, as a national trial lawyer, has encouraged investors in Vistagen Therapeutics to secure counsel before important deadlines.</data>
    </edge>
    <edge id="e16" source="18" target="13">
      <data key="d3">2.0</data>
      <data key="d4">leading trial attorney,...</data>
      <data key="d6">Laurence Rosen, as a leading trial attorney, has encouraged investors in Oracle Corporation to secure counsel before important deadlines.</data>
    </edge>
    <edge id="e17" source="19" target="13">
      <data key="d3">2.0</data>
      <data key="d4">leading trial attorney,...</data>
      <data key="d6">Laurence Rosen, as a leading trial attorney, has encouraged investors in Blue Owl to secure counsel before important deadlines.</data>
    </edge>
    <edge id="e18" source="20" target="13">
      <data key="d3">2.0</data>
      <data key="d4">leading trial attorney,...</data>
      <data key="d6">Laurence Rosen, as a leading trial attorney, has encouraged investors in Alexandria Real Estate Equities to secure counsel before important deadlines.</data>
    </edge>
    <edge id="e19" source="21" target="13">
      <data key="d3">2.0</data>
      <data key="d4">leading trial attorney,...</data>
      <data key="d6">Laurence Rosen, as a leading trial attorney, has encouraged investors in Mercury Systems Inc. to secure counsel before important deadlines.</data>
    </edge>
    <edge id="e20" source="22" target="13">
      <data key="d3">2.0</data>
      <data key="d4">national trial counsel,...</data>
      <data key="d6">Laurence Rosen, as a national trial counsel, has encouraged investors in Gauzy to secure counsel before important deadlines.</data>
    </edge>
    <edge id="e21" source="23" target="13">
      <data key="d3">2.0</data>
      <data key="d4">leading trial attorney,...</data>
      <data key="d6">Laurence Rosen, as a leading trial attorney, has encouraged investors in Maplebear Inc. (d/b/a Instacart) to secure counsel before important deadlines.</data>
    </edge>
    <edge id="e22" source="24" target="13">
      <data key="d3">2.0</data>
      <data key="d4">national trial lawyer,...</data>
      <data key="d6">Laurence Rosen, as a national trial lawyer, has encouraged investors in IMX Token to secure counsel before important deadlines.</data>
    </edge>
    <edge id="e23" source="25" target="13">
      <data key="d3">2.0</data>
      <data key="d4">trusted trial lawyer,...</data>
      <data key="d6">Laurence Rosen, as a trusted trial lawyer, has encouraged investors in Bitdeer to secure counsel before important deadlines.</data>
    </edge>
    <edge id="e24" source="11" target="0">
      <data key="d3">18.0</data>
      <data key="d4">Firm filed class...</data>
      <data key="d6">The Rosen Law Firm has filed a class action lawsuit on behalf of Vistagen Therapeutics investors</data>
    </edge>
    <edge id="e25" source="26" target="14">
      <data key="d3">2.0</data>
      <data key="d4">Bitdeer Technologies Group...</data>
      <data key="d6">The article about the Bitdeer Technologies Group legal deadline is published on Reflector.com</data>
    </edge>
    <edge id="e26" source="24" target="3">
      <data key="d3">8.0</data>
      <data key="d4">investigating potential securities...</data>
      <data key="d6">Rosen Law Firm is investigating potential securities claims related to the IMX tokens issued by Immutable</data>
    </edge>
    <edge id="e27" source="13" target="11">
      <data key="d3">43.0</data>
      <data key="d4">founding partner...</data>
      <data key="d6">Laurence Rosen is the founding partner of the Rosen Law Firm, a prominent legal practice that has gained recognition for its work in the field. Rosen has been lauded as a leader in his profession and has been named a "Titan of Plaintiffs' Bar," a prestigious accolade that underscores his expertise and influence.

The Rosen Law Firm, under Rosen's leadership, is currently representing investors in a securities class action against Oracle. This high-profile case showcases the firm's commitment to protecting the rights of its clients and its willingness to take on complex legal challenges.

Rosen's expertise and reputation have earned him a respected position within the legal community. As the founding partner of the Rosen Law Firm, he has built a practice that is known for its dedication to achieving successful outcomes for its clients. The firm's work in the Oracle securities class action is a testament to Rosen's ability to navigate complex legal landscapes and advocate effectively on behalf of his clients.

Overall, Laurence Rosen is a respected and accomplished legal professional who has made significant contributions to the field. His leadership of the Rosen Law Firm and his involvement in high-profile cases have solidified his reputation as a skilled and effective advocate.</data>
    </edge>
    <edge id="e28" source="12" target="11">
      <data key="d3">41.0</data>
      <data key="d4">attorney Rosen...</data>
      <data key="d6">Phillip Kim is an attorney at the Rosen Law Firm, a prominent law firm that specializes in class action lawsuits. Based on the information provided, Phillip Kim is currently handling two significant class action cases.

The first case involves a class action lawsuit against Vistagen Therapeutics, a biopharmaceutical company. Phillip Kim is leading the legal team representing the plaintiffs in this case. The lawsuit likely alleges some form of corporate misconduct or wrongdoing by Vistagen Therapeutics, which has resulted in financial losses or other damages for the affected investors or consumers.

The second case that Phillip Kim is handling at the Rosen Law Firm is a securities class action lawsuit against Oracle, a multinational technology company. In this case, Phillip Kim is representing a group of investors or shareholders who have suffered losses due to alleged securities fraud or other financial irregularities by Oracle.

The descriptions provided do not contain any contradictory information about Phillip Kim's role or the cases he is handling at the Rosen Law Firm. The consistent details across the descriptions suggest that Phillip Kim is a skilled and experienced attorney who is actively involved in high-profile class action lawsuits on behalf of his clients.

The Rosen Law Firm, where Phillip Kim is employed, is a well-known and respected law firm that specializes in class action litigation. The firm has a track record of successfully representing plaintiffs in complex cases against large corporations and has recovered significant settlements and awards for its clients.

In summary, Phillip Kim is an attorney at the Rosen Law Firm who is currently handling two significant class action lawsuits: one against Vistagen Therapeutics and another against Oracle. He is leading the legal teams in these cases, which likely involve allegations of corporate misconduct or financial irregularities that have resulted in losses for the affected parties. The Rosen Law Firm, where Phillip Kim works, is a reputable firm that specializes in class action litigation and has a history of successful outcomes for its clients.</data>
    </edge>
    <edge id="e29" source="0" target="11">
      <data key="d3">27.0</data>
      <data key="d4">ROSEN LAW FIRM...</data>
      <data key="d6">VISTAGEN THERAPEUTICS, INC. and ROSEN LAW FIRM

VISTAGEN THERAPEUTICS, INC. is a biopharmaceutical company that is facing a class action lawsuit filed by the ROSEN LAW FIRM on behalf of investors. The lawsuit alleges that VISTAGEN THERAPEUTICS, INC. provided false and misleading information to investors.

According to the ROSEN LAW FIRM, the class action lawsuit was filed against VISTAGEN THERAPEUTICS, INC. for allegedly providing false and misleading information to investors. The lawsuit seeks to represent all investors who purchased or acquired VISTAGEN THERAPEUTICS, INC. securities during a specific time period.

The ROSEN LAW FIRM is a national, investor-focused law firm that specializes in securities class actions and shareholder derivative litigation. The firm has a team of experienced attorneys who have successfully represented investors in a wide range of cases, including those involving allegations of corporate misconduct and securities fraud.

The lawsuit against VISTAGEN THERAPEUTICS, INC. is currently ongoing, and the outcome of the case remains to be seen. However, the allegations made by the ROSEN LAW FIRM suggest that the company may have engaged in practices that were not in the best interests of its investors.

It is important to note that the allegations made in the lawsuit have not been proven in court, and VISTAGEN THERAPEUTICS, INC. has not yet had the opportunity to respond to the claims. The company may have a different perspective on the events that led to the lawsuit, and it is possible that the allegations could be resolved in its favor.

Overall, the class action lawsuit filed by the ROSEN LAW FIRM against VISTAGEN THERAPEUTICS, INC. is a significant development that investors and the public should follow closely. The outcome of the case could have important implications for the company and its shareholders.</data>
    </edge>
    <edge id="e30" source="0" target="27">
      <data key="d3">1.0</data>
      <data key="d4">publicly traded company...</data>
      <data key="d6">Vistagen Therapeutics is a publicly traded company listed on the NASDAQ stock exchange</data>
    </edge>
    <edge id="e31" source="18" target="11">
      <data key="d3">18.0</data>
      <data key="d4">Firm filed securities...</data>
      <data key="d6">The Rosen Law Firm has filed a securities class action lawsuit against Oracle Corporation on behalf of investors who purchased Oracle senior notes</data>
    </edge>
    <edge id="e32" source="18" target="28">
      <data key="d3">8.0</data>
      <data key="d4">senior notes pursuant...</data>
      <data key="d6">Oracle Corporation issued senior notes pursuant to the Shelf Registration Statement filed with the SEC</data>
    </edge>
    <edge id="e33" source="18" target="29">
      <data key="d3">1.0</data>
      <data key="d4">Shelf Registration Statement...</data>
      <data key="d6">Oracle Corporation filed the Shelf Registration Statement with the SEC in order to issue senior notes</data>
    </edge>
    <edge id="e34" source="30" target="31">
      <data key="d3">18.0</data>
      <data key="d4">parent company Instacart...</data>
      <data key="d6">Maplebear Inc. is the parent company of Instacart</data>
    </edge>
    <edge id="e35" source="30" target="27">
      <data key="d3">16.0</data>
      <data key="d4">traded Nasdaq stock...</data>
      <data key="d6">Instacart is publicly traded on the Nasdaq stock exchange</data>
    </edge>
    <edge id="e36" source="30" target="11">
      <data key="d3">18.0</data>
      <data key="d4">Firm filed class...</data>
      <data key="d6">The Rosen Law Firm has filed a class action lawsuit on behalf of Instacart investors</data>
    </edge>
    <edge id="e37" source="30" target="32">
      <data key="d3">9.0</data>
      <data key="d4">initial public offering...</data>
      <data key="d6">Instacart had its initial public offering on this date</data>
    </edge>
    <edge id="e38" source="30" target="33">
      <data key="d3">9.0</data>
      <data key="d4">Instacart securities class...</data>
      <data key="d6">The class period for the Instacart securities class action lawsuit ended on this date</data>
    </edge>
    <edge id="e39" source="30" target="34">
      <data key="d3">1.0</data>
      <data key="d4">investors join Instacart...</data>
      <data key="d6">The deadline for investors to join the Instacart class action lawsuit as lead plaintiff is on this date</data>
    </edge>
    <edge id="e40" source="13" target="43">
      <data key="d3">10.0</data>
      <data key="d4">founder managing attorney...</data>
      <data key="d6">Laurence Rosen is the founder and managing attorney of The Rosen Law Firm, which he founded in 2001 to represent investors exclusively in securities fraud and corporate governance litigation.</data>
    </edge>
    <edge id="e41" source="13" target="35">
      <data key="d3">8.0</data>
      <data key="d4">from New York...</data>
      <data key="d6">Laurence Rosen graduated from New York University School of Law with a J.D. degree.</data>
    </edge>
    <edge id="e42" source="13" target="36">
      <data key="d3">8.0</data>
      <data key="d4">M.B.A. Finance...</data>
      <data key="d6">Laurence Rosen earned his M.B.A. in Finance and Accounting from the University of Chicago Graduate School of Business.</data>
    </edge>
    <edge id="e43" source="13" target="37">
      <data key="d3">8.0</data>
      <data key="d4">Economics from...</data>
      <data key="d6">Laurence Rosen earned his B.A. in Economics from Emory University.</data>
    </edge>
    <edge id="e44" source="13" target="38">
      <data key="d3">8.0</data>
      <data key="d4">law clerk...</data>
      <data key="d6">Laurence Rosen served as a law clerk to the Honorable Stanley S. Brotman, Senior United States District Judge for the District of New Jersey.</data>
    </edge>
    <edge id="e45" source="13" target="39">
      <data key="d3">14.0</data>
      <data key="d4">individual who been...</data>
      <data key="d6">Laurence Rosen is an individual who has been associated with the law firm Skadden Arps Slate Meagher &amp; Flom. According to the information provided, Rosen entered private practice as an associate at the Skadden Arps Slate Meagher &amp; Flom law firm in New York City. During his time at the firm, Rosen worked as an associate, participating in securities class action and derivative litigation matters.

The descriptions provided do not contain any contradictory information about Laurence Rosen or his association with Skadden Arps Slate Meagher &amp; Flom. The descriptions consistently indicate that Rosen was an associate at the Skadden Arps Slate Meagher &amp; Flom law firm, where he was involved in securities-related litigation matters.

In summary, Laurence Rosen is an individual who worked as an associate at the Skadden Arps Slate Meagher &amp; Flom law firm in New York City. During his time at the firm, Rosen participated in securities class action and derivative litigation matters.</data>
    </edge>
    <edge id="e46" source="13" target="40">
      <data key="d3">18.0</data>
      <data key="d4">lead attorney who...</data>
      <data key="d6">Laurence Rosen was the lead attorney who directed the successful litigation against Alibaba Holdings arising from its $25 billion IPO, achieving a $250 million settlement.</data>
    </edge>
    <edge id="e47" source="13" target="41">
      <data key="d3">16.0</data>
      <data key="d4">one lead attorneys...</data>
      <data key="d6">Laurence Rosen was one of the lead attorneys in the $110 million settlement obtained from FIAT following its merger with Chrysler and its listing on the NYSE.</data>
    </edge>
    <edge id="e48" source="13" target="42">
      <data key="d3">2.0</data>
      <data key="d4">one lead trial...</data>
      <data key="d6">Laurence Rosen was one of the lead trial attorneys in the fiduciary duty litigation against the Textainer partnerships arising from its sale of the partnership assets, resulting in a $10 million recovery for limited partners following a bench trial.</data>
    </edge>
    <edge id="e49" source="13" target="54">
      <data key="d3">9.0</data>
      <data key="d4">lawyer Rosen...</data>
      <data key="d6">Laurence Rosen is a lawyer at The Rosen Law Firm, P.A.</data>
    </edge>
    <edge id="e50" source="13" target="55">
      <data key="d3">9.0</data>
      <data key="d4">been named prestigious...</data>
      <data key="d6">Laurence Rosen has been named to the prestigious Lawdragon 500 Leading Plaintiff Financial Lawyers list.</data>
    </edge>
    <edge id="e51" source="44" target="54">
      <data key="d3">9.0</data>
      <data key="d4">lawyer Rosen...</data>
      <data key="d6">Phil Kim is a lawyer at The Rosen Law Firm, P.A.</data>
    </edge>
    <edge id="e52" source="44" target="55">
      <data key="d3">9.0</data>
      <data key="d4">been named prestigious...</data>
      <data key="d6">Phil Kim has been named to the prestigious Lawdragon 500 Leading Plaintiff Financial Lawyers list.</data>
    </edge>
    <edge id="e53" source="45" target="54">
      <data key="d3">9.0</data>
      <data key="d4">lawyer Rosen...</data>
      <data key="d6">Jacob Goldberg is a lawyer at The Rosen Law Firm, P.A.</data>
    </edge>
    <edge id="e54" source="45" target="55">
      <data key="d3">1.0</data>
      <data key="d4">been named prestigious...</data>
      <data key="d6">Jacob Goldberg has been named to the prestigious Lawdragon 500 Leading Plaintiff Financial Lawyers list.</data>
    </edge>
    <edge id="e55" source="46" target="54">
      <data key="d3">8.0</data>
      <data key="d4">Firm, announced proposed...</data>
      <data key="d6">The Rosen Law Firm, P.A. announced a proposed partial class action settlement on behalf of purchasers of the common units of SandRidge Mississippian Trust I.</data>
    </edge>
    <edge id="e56" source="47" target="54">
      <data key="d3">8.0</data>
      <data key="d4">Firm, announced proposed...</data>
      <data key="d6">The Rosen Law Firm, P.A. announced a proposed partial class action settlement on behalf of purchasers of the common units of SandRidge Mississippian Trust II.</data>
    </edge>
    <edge id="e57" source="48" target="54">
      <data key="d3">8.0</data>
      <data key="d4">Firm, announced proposed...</data>
      <data key="d6">The Rosen Law Firm, P.A. announced a proposed securities class action settlement on behalf of purchasers of Indivior PLC securities.</data>
    </edge>
    <edge id="e58" source="49" target="54">
      <data key="d3">8.0</data>
      <data key="d4">Firm, announced proposed...</data>
      <data key="d6">The Rosen Law Firm, P.A. announced a proposed class action settlement in the PPDAI Group Inc. securities litigation.</data>
    </edge>
    <edge id="e59" source="50" target="54">
      <data key="d3">8.0</data>
      <data key="d4">Firm, announced proposed...</data>
      <data key="d6">The Rosen Law Firm, P.A. announced a proposed class action settlement on behalf of purchasers of Acer Therapeutics Inc. common stock.</data>
    </edge>
    <edge id="e60" source="51" target="54">
      <data key="d3">10.0</data>
      <data key="d4">Firm, obtained $110...</data>
      <data key="d6">The Rosen Law Firm, P.A. obtained a $110 million settlement for Fiat Chrysler Automobiles N.V. investors.</data>
    </edge>
    <edge id="e61" source="52" target="54">
      <data key="d3">10.0</data>
      <data key="d4">Firm, obtained $250...</data>
      <data key="d6">The Rosen Law Firm, P.A. obtained a $250 million settlement for Alibaba Group Holding Limited investors.</data>
    </edge>
    <edge id="e62" source="53" target="54">
      <data key="d3">1.0</data>
      <data key="d4">Firm, appointed lead...</data>
      <data key="d6">The Rosen Law Firm, P.A. was appointed lead counsel in the Chanticleer Holdings, Inc. class action.</data>
    </edge>
    <edge id="e63" source="43" target="13">
      <data key="d3">20.0</data>
      <data key="d4">leads Rosen Law...</data>
      <data key="d6">Laurence Rosen founded and leads The Rosen Law Firm, which specializes in securities litigation on behalf of investors.</data>
    </edge>
    <edge id="e64" source="43" target="56">
      <data key="d3">8.0</data>
      <data key="d4">Firm located New...</data>
      <data key="d6">The Rosen Law Firm is located in New York City, where Laurence Rosen is based.</data>
    </edge>
    <edge id="e65" source="57" target="13">
      <data key="d3">16.0</data>
      <data key="d4">been recognized one...</data>
      <data key="d6">Laurence Rosen has been recognized as one of the top 100 trial lawyers in the United States by The National Trial Lawyers Top 100.</data>
    </edge>
    <edge id="e66" source="13" target="58">
      <data key="d3">7.0</data>
      <data key="d4">associate McCarter...</data>
      <data key="d6">Laurence Rosen worked as an associate at McCarter &amp; English, specializing in securities and business litigation.</data>
    </edge>
    <edge id="e67" source="13" target="59">
      <data key="d3">7.0</data>
      <data key="d4">general securities commercial...</data>
      <data key="d6">Laurence Rosen practiced general securities and commercial litigation at Solton Rosen &amp; Balakhovsky LLP in New York City before founding The Rosen Law Firm.</data>
    </edge>
    <edge id="e68" source="13" target="60">
      <data key="d3">9.0</data>
      <data key="d4">sole lead counsel,...</data>
      <data key="d6">Laurence Rosen, as sole lead counsel, secured a $250 million class action settlement for Alibaba Group Holdings Ltd. - the largest settlement involving a Chinese issuer.</data>
    </edge>
    <edge id="e69" source="13" target="61">
      <data key="d3">1.0</data>
      <data key="d4">co-lead counsel, secured...</data>
      <data key="d6">Laurence Rosen, as co-lead counsel, secured a $110 million class action settlement for Fiat Chrysler Automobiles, N.V.</data>
    </edge>
    <edge id="e70" source="11" target="62">
      <data key="d3">18.0</data>
      <data key="d4">Firm representing investors...</data>
      <data key="d6">The Rosen Law Firm is representing investors in a securities class action lawsuit against Alexandria Real Estate Equities, Inc. for allegedly providing false and misleading statements about its properties.</data>
    </edge>
    <edge id="e71" source="62" target="63">
      <data key="d3">1.0</data>
      <data key="d4">Equities, Inc. being...</data>
      <data key="d6">Alexandria Real Estate Equities, Inc. is being sued for allegedly providing false and misleading statements about the leasing value of its Long Island City property.</data>
    </edge>
    <edge id="e72" source="11" target="9">
      <data key="d3">18.0</data>
      <data key="d4">Firm representing investors...</data>
      <data key="d6">The Rosen Law Firm is representing investors in a class action lawsuit against Gauzy Ltd. for alleged false and misleading statements during the class period</data>
    </edge>
    <edge id="e73" source="0" target="64">
      <data key="d3">7.0</data>
      <data key="d4">positive results PALISADE-2...</data>
      <data key="d6">Vistagen cited the positive results of the PALISADE-2 clinical trial as evidence that the PALISADE-3 trial would also be successful</data>
    </edge>
    <edge id="e74" source="0" target="65">
      <data key="d3">1.0</data>
      <data key="d4">trial Vistagen's drug...</data>
      <data key="d6">The PALISADE-3 clinical trial for Vistagen's drug fasedienol is the subject of the lawsuit, with investors alleging Vistagen provided false and misleading information about it</data>
    </edge>
    <edge id="e75" source="0" target="67">
      <data key="d3">9.0</data>
      <data key="d4">issued common stock...</data>
      <data key="d6">Vistagen Therapeutics, Inc. issued the common stock that investors purchased during the class period</data>
    </edge>
    <edge id="e76" source="66" target="67">
      <data key="d3">1.0</data>
      <data key="d4">court March...</data>
      <data key="d6">Investors must move the court by March 16, 2026 to serve as lead plaintiff in the class action lawsuit regarding Vistagen common stock</data>
    </edge>
  </graph>
</graphml>